CG Oncology (CGON) Net Cash Flow (2023 - 2026)

CG Oncology's Net Cash Flow history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Net Cash Flow rose 100.58% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (up 78.66% YoY) and the FY2025 annual result came in at -$224.5 million, down 190.25% from the prior year.
• Net Cash Flow was $1.3 million for Q1 2026 at CG Oncology, up from -$12.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $213.7 million in Q4 2024 and bottomed at -$215.6 million in Q1 2025.
• A 4-year average of -$4.2 million and a median of -$2.0 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow soared 10745.59% — and 2025, when it tumbled 411.55%.
• CG Oncology's Net Cash Flow stood at -$2.0 million in 2023, then surged by 10745.59% to $213.7 million in 2024, then sank by 105.92% to -$12.6 million in 2025, then surged by 109.91% to $1.3 million in 2026.
• Business Quant data shows CGON's Net Cash Flow at $1.3 million in Q1 2026, -$12.6 million in Q4 2025, and $30.6 million in Q3 2025.